ashwini bakhade
by on June 18, 2024

Anti-obesity drugs refer to weight-loss medications used to manage unhealthy weight and obesity. Some of the commonly used anti-obesity drugs are Phentermine, Orlistat, Liraglutide, Naltrexone Bupropion, Naltrexone HCI and Bupropion HCI. They work by reducing appetite or absorbing fats from the food. Obesity has become a major health issue across the globe, primarily due to sedentary lifestyle and unhealthy dietary habits. This has boosted the demand for efficient weight management drugs and therapies. The prevalence of obesity is growing at an alarming rate worldwide. As per the WHO, over 1.9 billion adults aged 18 years and older were overweight. Of these over 650 million were obese in 2016. This has increased the burden on healthcare systems and boosted medical spending on weight management.

The Global Anti-Obesity Drug Market is estimated to be valued at US$ 2928.39 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others. The rising prevalence of obesity across the globe has fuelled the demand for anti-obesity drugs. As per WHO, more than 1.9 billion adults aged 18 years and older were overweight, and over 650 million were obese globally in 2016. Technological advancements in anti-obesity drug formulations are also aiding their adoption. Newer drug delivery systems are being developed to enhance efficacy and safety of weight loss medications.

Market Trends
Growing focus on combination therapy: Combining Anti-Obesity Drugs Market Size with lifestyle modifications and tailored diet plans is gaining traction. This multidisciplinary approach enhances weight loss results. Pharma companies are developing combination drug formulations for better efficacy.

Increasing clinical trials for new drug candidates: Obesity presents a major risk factor for many chronic diseases. This has accelerated R&D for more effective and safer anti-obesity drugs. Several candidates targeting novel pathways are in preclinical and clinical trial phases. This will expand the treatment landscape in the coming years.

Market Opportunities
Online weight management programs: Digital health solutions providing diet coaching, exercise tracking and prescription refills through telehealth can boost accessibility and compliance for anti-obesity medication use. This presents an opportunity for integrated care models.

Personalized weight loss approach: With advanced diagnostics, developing personalized weight loss plans catered to an individual's metabolism, lifestyle and genetics can drive better outcomes. This calls for more research on precision anti-obesity therapies.

Impact of COVID-19 on Anti-Obesity Drug Market Growth

The COVID-19 pandemic had a significant impact on the growth of the anti-obesity drug market globally. During the initial lockdown phases across various regions, there was decreased access to hospitals and healthcare facilities. This led to delays in non-emergency procedures and treatment plans. Many obesity treatment programs involving prescription drugs were put on hold. Moreover, disruptions in supply chains worldwide affected the timely availability of these drugs in the market. This negatively impacted the market growth in 2020.

However, as lockdowns eased in 2021, the market started recovering. Telemedicine became a major healthcare delivery method with many obesity specialists resuming digital consultations and management of chronic conditions. They renewed prescriptions for anti-obesity medications through virtual visits. Also, with many people facing job losses or financial difficulties during the pandemic, weight gain became a major issue. This increased the focus on losing excess weight and controlling obesity again through prescription therapies. The demand also rose as patients searched for safer treatment plans to manage their condition from home without risks of contracting the virus through physical hospital visits. If supply chain challenges can be addressed, the future market growth trajectory is expected to be positive with growing obesity rates post-pandemic.

Geographical Regions with Highest Market Concentration

North America dominated the global anti-obesity drug market in terms of value in 2024. This is attributed to the high prevalence of obesity in the region, especially in the United States. According to the Organization for Economic Co-operation and Development (OECD), the U.S. has one of the highest obesity rates, with over 40% of the adult population being obese. Additionally, strong healthcare infrastructure and high spending on obesity management treatments in this region fueled the regional market growth.

Europe was the second largest regional market for anti-obesity drugs in 2024. Countries like Germany, France, United Kingdom have witnessed increasing demand for prescription drugs to tackle obesity issues. Also, growing awareness about health risks of obesity and presence of favorable reimbursement policies support the market growth in Europe.

Fastest Growing Regional Market

The anti-obesity drug market in Asia Pacific region is projected to witness the fastest growth during the forecast period. Rising obesity rates especially in middle-income countries like China and India present significant growth opportunities. In addition, increasing healthcare expenditures, improving access to modern obesity treatment methods, and expanding medical insurance coverage will aid the regional market expansion through 2031. Heightened efforts by government and private organizations to curb obesity are also boosting the prescription drug adoption for weight management in Asia Pacific. The market holds huge untapped growth potential in this region.

Get more insights on This Topic- Anti-Obesity Drugs Market

Posted in: Business
Be the first person to like this.